Storyboard

FDA to Probe How It Approved Biogen's Controversial Alzheimer's Drug

The head of the Food and Drug Administration is calling for an investigation into how her agency approved Biogen's Aduhelm, the first drug to treat Alzheimer's Disease in nearly two decades. This despite failing to receive an endorsement from an independent panel of experts, who said there was inconclusive evidence of the drug's efficacy. Recently, another panel ruled Aduhelm shows no benefit, and major U.S. hospitals and insurers have already declined to prescribe it.

Avatar - The Science Desk
Curated by
The Science Desk
    • Medical Conditions
    • Alzheimer's Disease
    • Health
    • FDA
    • Biogen
FDA to Probe How It Approved Biogen's Controversial Alzheimer's Drug
Continue to read
13 stories in this Storyboard
    FDA calls for federal investigation into its controversial Alzheimer’s drug approval

    FDA calls for federal investigation into its controversial Alzheimer’s drug approval

    The head of the Food and Drug Administration has called for a wide-ranging federal investigation into the approval of Biogen’s treatment for …

    Panel says Biogen's Aduhelm Alzheimer's drug shows no benefit

    Panel says Biogen's Aduhelm Alzheimer's drug shows no benefit

    verified_publisher
    FOX Business - Alexandria Hein

    An expert panel unanimously voted that Biogen’s controversial Alzheimer’s drug does not provide more benefit to patients than supportive care. The latest blow dealt to Aduhelm comes in the same week that two major health centers said they will not carry the drug. The Institute for Clinical and …

    Further Reading

    Learn more about Biogen's Alzheimer's Drug along with other innovations in health and medicine.

    Why the FDA's Approval of Biogen's Alzheimer's Drug is So Controversial
    1.

    Why the FDA's Approval of Biogen's Alzheimer's Drug is So Controversial

    By The Science Desk

More stories from Medical Conditions